|1.||Li, Xiaohong: 6 articles (09/2015 - 05/2010)|
|2.||Luo, Xiaoming: 6 articles (09/2015 - 05/2010)|
|3.||Nie, Fang: 4 articles (01/2015 - 04/2011)|
|4.||Xu, B: 4 articles (09/2001 - 04/2000)|
|5.||Wang, Wei: 3 articles (07/2015 - 01/2011)|
|6.||Yao, Yang: 3 articles (06/2014 - 08/2006)|
|7.||Song, Haixing: 3 articles (01/2014 - 09/2012)|
|8.||Xiao, Shu Dong: 3 articles (01/2012 - 04/2011)|
|9.||Xu, Xi Tao: 3 articles (01/2012 - 04/2011)|
|10.||Tong, Jin Lu: 3 articles (01/2012 - 04/2011)|
10/15/2013 - "Compared to commercial HCPT injection, in vivo experiments with HCPT nanosuspensions showed significantly increased HCPT concentrations in the blood and all tissues of the tested as well as improved tumor targetability and liver targetability. "
09/01/2001 - "Both forms of HCPT were effective against tumor growth, but C-HCPT was more effective than O-HCPT, the latter could be converted into the former under certain conditions."
10/15/2013 - "Hydroxycamptothecin (HCPT) has shown activity against a broad spectrum of cancers, but its therapeutic efficacy is impaired by its poor solubility and delivery challenges. "
07/06/2015 - "In this study we demonstrated that when HCPT and DOX are combined into a single nanoparticle, their toxicity to tumor cells in vitro is synergistically enhanced. "
04/01/2015 - "In the current study, the transcriptional stability of 30 candidate reference genes was investigated in cancer cells following treatment with PTX and HCPT. "
|2.||Urinary Bladder Neoplasms (Bladder Cancer)
12/01/2010 - "The efficacy of EPI and THP was significantly better than HCPT in the prevention of bladder cancer recurrence."
01/01/2013 - "In this study, we investigated whether genistein could sensitize bladder cancer cell lines and bladder epithelial cell BDEC cells to HCPT treatment, and investigated the possible underlying molecular mechanisms. "
01/01/2013 - "Genistein and HCPT synergistically inhibited bladder cell growth and proliferation, and induced G2/M phase cell cycle arrest and apoptosis in TCCSUP bladder cancer cell and BDEC cell. "
01/01/2013 - "Genistein could significantly and dose-dependently sensitize multiple bladder cancer cell lines and BDEC cells to HCPT-induced apoptosis both in vitro and in vivo. "
01/01/2013 - "Genistein sensitizes bladder cancer cells to HCPT treatment in vitro and in vivo via ATM/NF-κB/IKK pathway-induced apoptosis."
|3.||Lung Neoplasms (Lung Cancer)
08/01/2008 - "In-vivo experiments indicated that PEG-NLCs loaded with HCPT have superior efficacy against A549 lung cancer compared with HCPT solution and NLCs. "
06/01/2011 - "We characterized the HCPT-loaded nanoparticles and determined their effects on lung cancer cell viability and apoptosis by using immunofluorescence light microscopy and SDS-PAGE/immunoblots. "
08/01/2008 - "These results suggest that PEG-NLCs is a promising delivery system for HCPT in the treatment of lung cancer."
01/01/2008 - "It was a promising carrier to increase therapeutic effect of HCPT in treating lung cancer."
06/01/2014 - "At the end, the mixtures of Q and HCPT were tested in terms of cytotoxicity on the human lung cancer cell line A549 and human leukemia cell line K562 to compare their reactivity with the free HCPT and the comparative cytotoxic activity was got for A549 and K562."
|4.||Hepatocellular Carcinoma (Hepatoma)
01/01/2013 - "The results of this study show GL-BSA-HCPT to be a promising new vehicle for hepatocellular carcinoma-targeting therapy."
08/01/2000 - "To study the differentiation-inducing effect of hydroxycamptothecin (HCPT) on hepatoma Hep G2 cells. "
07/01/1999 - "The results of this study suggest that the anti-hepatoma effect of HCPT may result from apoptosis induction and cell cycle disturbance."
08/01/2006 - "Our results indicate that HCPT can inhibit proliferation and induce apoptosis of human hepatoma SMMC-7721 cells. "
07/01/1999 - "The results showed that HCPT inhibited proliferation of human hepatoma Hep G2, Bel-7402 and Bel-7404 cells at an optimal concentration of 0.1 microg/ml. This growth inhibition was dose and time dependent, and was accompanied by evidence of apoptotic changes and cell cycle perturbation in Hep G2 cells. "
|5.||Breast Neoplasms (Breast Cancer)
07/06/2015 - "Synergistically Enhanced Therapeutic Effect of a Carrier-Free HCPT/DOX Nanodrug on Breast Cancer Cells through Improved Cellular Drug Accumulation."
04/01/1998 - "In the present study, we characterized the in vitro and in vivo apoptotic pathways induced by HCPT and CPT in the human breast cancer cell lines MCF-7 and MDA-MB-468. "
06/01/1997 - "These studies indicate that HCPT and CPT are of potential use in treatment of breast cancer, providing the basis for the design of future human trials with these anticancer drugs."
06/01/1997 - "The purpose of the present study was 2-fold, to determine the in vitro and in vivo activity of HCPT and CPT against human breast cancer and to determine the pharmacokinetics of the two drugs to better understand how they can best be used therapeutically. "
07/06/2015 - "The carrier-free HCPT/DOX nanoparticles demonstrated enhanced synergistic cytotoxicity against breast cancer cells in vitro, while an antagonistic effect was observed when HCPT and DOX were directly mixed at high concentration. "
|1.||Type I DNA Topoisomerases (Topoisomerase I)
|4.||Small Interfering RNA (siRNA)
|6.||Dimethyl Sulfoxide (DMSO)
|10.||DNA (Deoxyribonucleic Acid)
|1.||Drug Therapy (Chemotherapy)
|3.||Heterologous Transplantation (Xenotransplantation)